PROGRESS IN ANTI-TOXOPLASMA GONDII DRUG DEVELOPMENT:CURRENT STATUS,DIRECTION,AND CHALLENGES
10.3969/j.issn.1005-0507.2025.01.010
- VernacularTitle:抗弓形虫药物研究进展:现状、方向及挑战
- Author:
Ying-Mei LAI
1
;
Xun-Hui ZHUO
;
Zi JIN
Author Information
1. 杭州医学院,杭州 310000
- Keywords:
Toxoplasma gondii;
Anti-Toxoplasma drugs;
Mechanism of action;
Drug targets
- From:
Acta Parasitologica et Medica Entomologica Sinica
2025;32(1):52-59
- CountryChina
- Language:Chinese
-
Abstract:
Toxoplasma gondii is an opportunistic pathogenic protozoan that causes zoonotic toxoplasmosis and is capable of infecting almost all warm-blooded animals,including humans.T.gondii infection is a globally prevalent zoonosis,posing a particularly high risk to immunocompromised populations.It presents a serious threat to public health and animal husbandry due to its complex life cycle and wide host range.Currently,the prevention and treatment of toxoplasmosis rely primarily on drugs,with a combination of sulfadiazine and pyrimethamine being the first choice in clinical practice.However,limitations in efficacy,side effects,and drug resistance restrict its widespread use.While some progress has been made in the development of anti-Toxoplasma drugs,no ideal treatment has yet been approved for market release or clinical trials.This paper reviews recent progress on the mechanisms of action and targets of novel anti-Toxoplasma drugs based on relevant studies.It aims to provide new ideas for future drug research and development while highlighting the opportunities and challenges in the field.
